Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Withdrawn × nintedanib × Clear all

Phase

Phase 2 2 Phase 1/2 1

Status

Terminated 2 Completed 2 Withdrawn 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Carcinoma, Non-Small-Cell Lung 1 Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 28 pembrolizumab 22 Fluorouracil 17 Cisplatin 17 Bevacizumab 17 Nivolumab 16 Capecitabine 16 Leucovorin 15 Dexamethasone 14 Carboplatin 13 avelumab 12 Oxaliplatin 12 Radiosurgery 11 Gemcitabine 11 Rituximab 10 Radiotherapy 10 Lenalidomide 10 ALT-803 10 venetoclax 9 fludarabine 9 Taxes 9 Omacor 9 Azacitidine 9 130-nm albumin-bound paclitaxel 9 Paclitaxel 8 Docetaxel 8 Bortezomib 8 fludarabine phosphate 7 Melphalan 7 Irinotecan 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03361319 2020-11-24

N3

Royal Marsden NHS Foundation Trust

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡